First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023
Eurosurveillance·
- DOI
- 10.2807/1560-7917.es.2026.31.3.2500431
- PMID
- —
- PMCID
- —
- OpenAlex
- W7125562433
- Study type
- Journal article
- Publisher
- European Centre for Disease Control and Prevention (ECDC)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The investigation demonstrates the value of pharyngeal swabbing for outbreak strain identification and provides initial safety evidence for off-label use of MenB-fHbp vaccine in young children who had previously received 4CMenB vaccination.
Structured evidence summary
Research question
The report describes the public health response to a nursery outbreak of serogroup B invasive meningococcal disease in England, including the off-label use of MenB-fHbp vaccine in young children previously immunised with 4CMenB.
Study design
Outbreak investigation and public health intervention report. Following two cases of invasive meningococcal disease in a nursery, an incident management team conducted pharyngeal swabbing of contacts, strain characterization, and administered two doses of MenB-fHbp vaccine four weeks apart to 38 children and staff.
Population and setting
A nursery in England with 39 children and nine staff members. The two index cases were aged 2 and 3 years and had been fully vaccinated with 4CMenB.
Main findings
Pharyngeal swabbing identified two MenB isolates matching the index case. Laboratory testing revealed the outbreak strain was not covered by the 4CMenB vaccine. Thirty-eight children and all staff received two doses of MenB-fHbp vaccine without serious adverse events.
Public-health relevance
The investigation demonstrates the value of pharyngeal swabbing for outbreak strain identification and provides initial safety evidence for off-label use of MenB-fHbp vaccine in young children who had previously received 4CMenB vaccination.
Important limitations
This summary relies on the supplied single-article abstract and bibliographic metadata. Full interpretation of vaccine immunogenicity, follow-up duration, and clinical decision-making context requires review of the complete publication.
GIDS interpretation
This peer-reviewed journal article describing a November 2023 outbreak response in the United Kingdom is discoverable through disease (Meningococcal disease), country, and topic classifiers (Outbreak investigation, Vaccination). The report documents a public health intervention rather than ongoing surveillance data.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 7 auditable classifier relationships to diseases, places, topics, and study design.